ImClone Systems has received approval from the FDA to manufacture multiple products at its BB50 manufacturing facility. This approval significantly expands ImClone’s total available production volume capacity for its proprietary pipeline of novel antibodies, which are now entering late-stage clinical development. “This multi-product FDA approval of BB50 significantly enhances ImClone’s operational flexibility as we scale up production of our robust pipeline of proprietary antibodies for the g...